TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial 2 (COMET2): A Randomized Trial of the Effect of Progressive Addition Lenses Versus Single Vision Lenses on Low Myopia Associated With Large Accommodative Lags and Near Esophoria in Children
Brief Summary: The purpose of the study is to determine if progressive addition lenses (PALs) versus single vision lenses (SVLs) slow the progression of low myopia in children with poor accommodative responses (i.e., large accommodative lags) and near esophoria.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Arm Label: Dual Focus Soft Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Dual Focus Soft Contact Lens | Arm Label: Single Vision Soft Contact Lens; Type: PLACEBO_COMPARATOR; Interventions: Device: Single Vision Soft Contact Lens | Intervention Type: DEVICE; Name: Dual Focus Soft Contact Lens; Assigned to Arm(s): Dual Focus Soft Contact Lens | Intervention Type: DEVICE; Name: Single Vision Soft Contact Lens; Assigned to Arm(s): Single Vision Soft Contact Lens
C: Arm Label: Bifocal Contact Lenses; Type: EXPERIMENTAL; Interventions: Device: Bifocal Contact Lenses | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo Control | Intervention Type: DEVICE; Name: Bifocal Contact Lenses; Assigned to Arm(s): Bifocal Contact Lenses | Intervention Type: DEVICE; Name: Placebo Control; Assigned to Arm(s): Control
D: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aminocaproic Acid and Bleeding in Spinal Surgery
Brief Summary: Individuals who undergo spine surgery often have a significant loss of blood and may require multiple blood transfusions. Research has shown that epsilon-aminocaproic acid (EACA) may reduce the amount of blood lost during surgery, which would decrease the number of blood transfusions required. This study will evaluate the safety and effectiveness of EACA at reducing blood loss and the need for blood transfusions in individuals undergoing spine surgery.


Options:
A: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Epsilon Aminocaproic Acid; Type: EXPERIMENTAL; Interventions: Drug: Epsilon aminocaproic acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline | Intervention Type: DRUG; Name: Epsilon aminocaproic acid; Assigned to Arm(s): Epsilon Aminocaproic Acid
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Epsilon-Aminocaproic Acid (EACA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Epsilon-Aminocaproic Acid (EACA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: aprotinin or tranexamic acid; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Morbidity in First Episode Schizophrenia, Part II
Brief Summary: This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Patients who do not improve with these medications receive clozapine as their third medication trial.


Options:
A: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: lifestyle intervention; Assigned to Arm(s): N/A
B: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Olanzapine (open-label treatment period); Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine (open-label treatment period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Participants will take aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Participants will take risperidone; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Participants will take aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Participants will take risperidone
D: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AOT (Acridine Orange and Taurolidine) Trial: a Survey on Diagnosis and Prevention of Catheter-Related Infections in Patients on Home Parenteral Nutrition
Brief Summary: Total parenteral (intravenous) nutrition in the home setting (Home TPN or HPN) is a life saving strategy in patients who suffer from severe intestinal failure. Unfortunately, this treatment modality remains complicated by the development of frequent infectious complications. This especially relates to the device that is used to establish venous access, mostly a catheter (Hickman-Broviac type) or a port-a-cath.

Taurolodine is an antimicrobial agent without any known side effects or resistance-related problems that holds promise as an effective antibiotic lock solution to prevent catheter infections, as demonstrated recently in a pilot study in HPN patients \[Jurewitsch, 2005\].

In addition, recently a test has been described which may enable to confirm a suspected diagnosis of central line infection within one hour, the so-called Acridine Orange Leukocyte Cytospin test (AOLC) \[Bong, 2003\]. For this test, blood that is drawn from the central line is stained with the fluorescent dye acridine orange. Next, microscopic evaluation for the presence of micro-organisms takes place. Implementation of this test might enable to start treatment of the infection and prevent unnecessary removal of non-infected central lines without the necessity to several days wait for culture results.


Options:
A: Arm Label: AAT-023 (Zuragen Arm); Type: EXPERIMENTAL; Interventions: Device: AAT-023 solution (Zuragen) | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DEVICE; Name: AAT-023 solution (Zuragen); Assigned to Arm(s): AAT-023 (Zuragen Arm) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
B: Intervention Type: DRUG; Name: taurolidine; Assigned to Arm(s): N/A
C: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily
D: Arm Label: 30 % ethanol/ 4 % sodium citrate group; Type: EXPERIMENTAL; Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution | Arm Label: Heparin 1000 U/ml; Type: EXPERIMENTAL; Interventions: Drug: Heparin 1000 u / ml | Intervention Type: OTHER; Name: 30 % ethanol / 4% sodium citrate catheter locking solution; Assigned to Arm(s): 30 % ethanol/ 4 % sodium citrate group | Intervention Type: DRUG; Name: Heparin 1000 u / ml; Assigned to Arm(s): Heparin 1000 U/ml

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AOT (Acridine Orange and Taurolidine) Trial: a Survey on Diagnosis and Prevention of Catheter-Related Infections in Patients on Home Parenteral Nutrition
Brief Summary: Total parenteral (intravenous) nutrition in the home setting (Home TPN or HPN) is a life saving strategy in patients who suffer from severe intestinal failure. Unfortunately, this treatment modality remains complicated by the development of frequent infectious complications. This especially relates to the device that is used to establish venous access, mostly a catheter (Hickman-Broviac type) or a port-a-cath.

Taurolodine is an antimicrobial agent without any known side effects or resistance-related problems that holds promise as an effective antibiotic lock solution to prevent catheter infections, as demonstrated recently in a pilot study in HPN patients \[Jurewitsch, 2005\].

In addition, recently a test has been described which may enable to confirm a suspected diagnosis of central line infection within one hour, the so-called Acridine Orange Leukocyte Cytospin test (AOLC) \[Bong, 2003\]. For this test, blood that is drawn from the central line is stained with the fluorescent dye acridine orange. Next, microscopic evaluation for the presence of micro-organisms takes place. Implementation of this test might enable to start treatment of the infection and prevent unnecessary removal of non-infected central lines without the necessity to several days wait for culture results.


Options:
A: Arm Label: 30 % ethanol/ 4 % sodium citrate group; Type: EXPERIMENTAL; Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution | Arm Label: Heparin 1000 U/ml; Type: EXPERIMENTAL; Interventions: Drug: Heparin 1000 u / ml | Intervention Type: OTHER; Name: 30 % ethanol / 4% sodium citrate catheter locking solution; Assigned to Arm(s): 30 % ethanol/ 4 % sodium citrate group | Intervention Type: DRUG; Name: Heparin 1000 u / ml; Assigned to Arm(s): Heparin 1000 U/ml
B: Arm Label: AAT-023 (Zuragen Arm); Type: EXPERIMENTAL; Interventions: Device: AAT-023 solution (Zuragen) | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DEVICE; Name: AAT-023 solution (Zuragen); Assigned to Arm(s): AAT-023 (Zuragen Arm) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
C: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily
D: Intervention Type: DRUG; Name: taurolidine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.


Options:
A: Arm Label: Pamidronate and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pamidronate, Drug: placebo | Arm Label: Zoledronic acid and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic acid, Drug: placebo | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Pamidronate and placebo | Intervention Type: DRUG; Name: Zoledronic acid; Assigned to Arm(s): Zoledronic acid and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Pamidronate and placebo, Zoledronic acid and placebo
B: Arm Label: Arm 1: Clodronate; Type: EXPERIMENTAL; Interventions: Drug: clodronate | Arm Label: Arm 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: clodronate; Assigned to Arm(s): Arm 1: Clodronate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 2: Placebo
C: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
D: Arm Label: Zometa; Type: EXPERIMENTAL; Interventions: Drug: Zometa, Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Arm Label: No Zometa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Zometa | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: RADIATION; Name: External beam radiation; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: PROCEDURE; Name: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection; Assigned to Arm(s): No Zometa, Zometa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.


Options:
A: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
B: Arm Label: Arm I: Thal/ZLD; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: zoledronic acid | Arm Label: Arm II: ZLD; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I: Thal/ZLD | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Arm I: Thal/ZLD, Arm II: ZLD
C: Arm Label: Thalidomide + Bisphosphonate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate, Drug: Thalidomide, Drug: Zometa | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Thalidomide + Bisphosphonate
D: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD
Brief Summary: This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg
B: Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline
D: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: risedronate (including placebo) | Intervention Type: DRUG; Name: risedronate (including placebo); Assigned to Arm(s): A
B: Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: SubStudy: Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Substudy: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Non-steroidal aromatase inhibitor therapy; Assigned to Arm(s): Denosumab, Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): SubStudy: Zoledronic Acid | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Substudy: Standard of Care
D: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: denosumab | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): zoledronic acid | Intervention Type: BIOLOGICAL; Name: denosumab; Assigned to Arm(s): denosumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer


Options:
A: Arm Label: Zoledronic acid + androgen deprivation therapy; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Arm Label: Placebo + androgen deprivation therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Drug: androgen deprivation therapy, Drug: GnRH agonist, Dietary Supplement: Calcium supplement, Dietary Supplement: Vitamin D | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic acid + androgen deprivation therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo + androgen deprivation therapy | Intervention Type: DRUG; Name: androgen deprivation therapy; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium supplement; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo + androgen deprivation therapy, Zoledronic acid + androgen deprivation therapy
B: Arm Label: AMG 162; Type: EXPERIMENTAL; Interventions: Drug: AMG 162 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AMG 162; Assigned to Arm(s): AMG 162 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: denosumab | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): zoledronic acid | Intervention Type: BIOLOGICAL; Name: denosumab; Assigned to Arm(s): denosumab
D: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Risedronate | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: C